July 2007

Anti-inflammatory effects of pioglitazone and/or simvastatin in patients with distinct clinical risk for cardiovascular complications

September 10, 2008

Lipids

Statins are the most commonly used pharmacologic intervention in patients with increased cardiovascular risk. In addition to their beneficial effect on the atherogenic lipid profile, they have been shown to exert several pleiotrophic effects, including the reduction of low-grade inflammation. Thiazolidinediones (TZDs) are a new class of antidiabetic drugs that have been shown to improve insulin sensitivity and to reduce cardiovascular risk in patients with type 2 diabetes. Our study is the first to show a complementary effect of TZD and statin treatment on several cardiovascular risk factors in subjects without diabetes. These findings may have important implications for further discussion on cardiovascular risk reduction, especially for patients with metabolic syndrome.

One drug, so many off-target beneficial effects?

September 10, 2008

Lipids

The background required for assessing this paper by Hanefeld and Forst is derived from clinical studies using statin and peroxisome proliferator-activated receptors (PPAR)γ agonists.

Assessing risk through "inspired" care

September 10, 2008

Lipids

This retrospective subanalysis of the Adenosine Sestamibi SPECT Post-Infarction Evaluation (INSPIRE) trial shows that early adenosine sestamibi stress testing is not only safe early after myocardial infarction (MI), but can also be very useful to identify patients at very low risk for events in the first year after discharge.

Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia

September 10, 2008

Lipids

The effects of recurrent tachycardia after resolution of cardiomyopathy have not been thoroughly assessed. We evaluated and followed 24 patients with tachycardia-induced cardiomyopathy for more than 12 years. Our observations showed that patients with tachycardia-induced cardiomyopathy may be at long-term risk for sudden death. Surreptitious cardiomyopathy due to occult ultrastructural changes may persist. It has yet to be determined whether rapid and aggressive rate control would prevent structural damage to risk of sudden cardiac death.

Primary aldosteronism in hypertensive patients

September 10, 2008

Lipids

We evaluated the prevalence of primary aldosteronism in subjects newly diagnosed with hypertension who were referred to specialized hypertension centers. An aldosterone-producing adenoma was diagnosed in the subjects with lateralized aldosterone secretion, adenoma at surgery and on pathologic evaluation, and a blood pressure fall after adrenalectomy. Evidence of excess autonomous aldosterone secretion without such criteria led to a diagnosis of idiopathic hyperaldosteronism. Aldosterone-producing adenoma and idiopathic hyperaldosteronism were conclusively diagnosed in 4.8% and 6.4% of the subjects, respectively. Thus, with a prevalence of 11.2%, primary aldosteronism is quite common in patients with newly diagnosed hypertension.

Alcohol and hypertension

September 10, 2008

Lipids

To determine whether alcohol-associated hypertension carries risks similar to those of hypertension in abstainers or light drinkers, we prospectively studied cardiovascular sequelae separately in heavy drinkers, light drinkers, and abstainers. The risk of all outcomes was progressively higher for increasing blood pressure categories, with similar associations in each alcohol category. These data indicate that the risks of hypertension are independent of the amount of alcohol intake.

Covering Your Assets: Protecting Your Home From Lawsuit Risk

August 01, 2007

Lipids

The family home represents most people's largest source of wealth and personal savings. In many parts of the country, dramatic increases in housing prices have made real estate the new investment...